| Company Name: |
InvivoChem |
| Tel: |
+1-708-310-1919 +1-13798911105 |
| Email: |
sales@invivochem.cn |
TAI-95 tosylate manufacturers
- T-1101 tosylate
-
- $34.00
-
2026-07-15
- CAS:2250404-95-4
- Purity: 98.47%
- Supply Ability: 10g
|
| | TAI-95 tosylate Basic information |
| Product Name: | TAI-95 tosylate | | Synonyms: | TAI-95 tosylate;T-1101 tosylate (TAI-95 tosylate);N-(4-(4-((5-(2-Methoxyethoxy)pyrazin-2-yl)thio
)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinami
de 4-methylbenzenesulfonate;TAI95,T1101 tosylate,TAI-95,T1101,Apoptosis,Inhibitor,inhibit,T 1101,T-1101,PPI,TAI 95,Hec1/Nek2,T 1101 tosylate;T-1101 tosylate, 10 mM in DMSO;T-1101 tosylate ，E2402 | | CAS: | 2250404-95-4 | | MF: | C31H31N5O6S3 | | MW: | 665.8 | | EINECS: | | | Product Categories: | | | Mol File: | 2250404-95-4.mol |  |
| | TAI-95 tosylate Chemical Properties |
| storage temp. | Inert atmosphere,Store in freezer, under -20°C | | form | Solid | | color | Light yellow to yellow |
| | TAI-95 tosylate Usage And Synthesis |
| Uses | T-1101 tosylate (TAI-95 tosylate) is the tosylate salt form of T-1101 (HY-120356). T-1101 tosylate is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 tosylate blocks the interaction between Hec1 and NEK2, exhibits cytotoxicity in human liver cancer cells with GI50 of 15-70 nM. T-1101 tosylate induces apoptosis in Huh-7. T-1101 tosylate exhibits antitumor efficacy in mouse models[1]. | | in vivo | T-1101 tosylate shows good oral bioavailability and thermal stability [2].
Oral co-administration of T-1101 tosylate (2.5 mg/kg; p.o.; twice per day) halves the dose of sorafenib (25 mg/kg to 12.5 mg/kg) required to exhibit comparable in vivo activity towards Huh-7 xenografts [2].
T-1101 tosylate (2.5 mg/kg; p.o.; twice per day) shows significant in vivo activity in mice bearing various human cancer xenografts[2].
| Animal Model: | SCID mice bearing human Huh-7, BT-474, MCF-7, and MDA-MB-231 xenografts[2] | | Dosage: | 25 mg/kg, 50 mg/kg | | Administration: | Oral administration; twice per day; 28 days | | Result: | Showed significant in vivo activity in mice bearing various human cancer xenografts. |
| | IC 50 | NEK2 | | References | [1] Huang LY, et al., Inhibition of Hec1 as a novel approach for treatment of primary liver cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):511-20. DOI:10.1007/s00280-014-2540-7
[2] Chuang SH, et al. Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy. Eur J Med Chem. 2020 Apr 1;191:112118. DOI:10.1016/j.ejmech.2020.112118 |
| | TAI-95 tosylate Preparation Products And Raw materials |
|